Project Oncology®

187 Folgen

1. Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

   Vom: 23.12.2024
2. Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01

   Vom: 23.12.2024
3. Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases

   Vom: 23.12.2024
4. Understanding Heparin Resistance: Underlying Mechanisms and Alternative Treatment Options

   Vom: 16.12.2024
5. The Future of ITP Care: Exploring New Treatments

   Vom: 16.12.2024
6. Understanding iMCD Through RNA Sequencing

   Vom: 16.12.2024
7. NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker

   Vom: 13.12.2024
8. Diagnosing Castleman Disease: Key Considerations

   Vom: 10.12.2024
9. Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells

   Vom: 9.12.2024
10. Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy

    Vom: 27.11.2024
11. EMERALD Expert Views: Managing ER+/HER2-, ESR1m mBC Disease Progression Post ET+CDK4/6i

    Vom: 26.11.2024
12. The Long-Term Safety of Momelotinib for Myelofibrosis: A Poster from ASH

    Vom: 29.10.2024
13. Poster Pearl: Elacestrant + Abemaciclib for ER+/HER2- Metastatic Breast Cancer

    Vom: 29.10.2024
14. Investigating the Impact of Momelotinib on Myelofibrosis Patients: A Poster from ASH

    Vom: 29.10.2024
15. Enhancing Outcomes in Relapsed/Refractory B-ALL with CAR T-Cell Therapy

    Vom: 16.10.2024
16. Momelotinib vs. Ruxolitinib: Comparing Efficacy in Myelofibrosis and Anemia Patients

    Vom: 2.10.2024
17. From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases

    Vom: 16.9.2024
18. Insights from ICARUS-Lung01: Efficacy and Safety of Dato-DXd for NSCLC

    Vom: 9.9.2024
19. Myeloma Matters: Bispecific Antibody Horizons: Dosing Strategies and Meeting Updates in Myeloma Care

    Vom: 15.8.2024
20. The Promise of MCED Testing: Easing the Burden of Cancer Screening Anxiety

    Vom: 6.8.2024